Quilaban introduces new Digital PCR technology for faster, more accurate diagnostics

QIAGEN’s QIAcuityDx solution enables the detection of diseases such as cancer and infections with greater sensitivity – and in just two hours.

Quilaban has introduced in Portugal QIAGEN’s QIAcuityDx Digital PCR technology, which allows faster and more accurate detection of diseases such as cancer, severe infections, and antibiotic resistance.

This new QIAGEN technology enables a more sensitive and precise analysis of genetic material, even when present in minimal quantities. As a result, clinical laboratories can obtain faster results – in as little as two hours – that are more reliable and provide greater detail.

The system offers clear advantages for early diagnosis and personalised care, particularly in oncology, clinical microbiology, and infectious diseases.

Alongside this new equipment, more than 35 assays have also been launched for the detection of microbial DNA, covering tropical, sexually transmitted, and urinary tract infections. These solutions further reinforce QIAGEN’s role in epidemiological surveillance and support for public health.

By bringing this technology to Portugal, Quilaban is contributing to laboratories’ access to faster, more accurate, and less invasive methods – placing innovation at the service of healthcare and quality of care.

This innovation is part of the long-standing collaboration that Quilaban has maintained with QIAGEN in Portugal for over two decades. Through this partnership, a wide range of leading laboratory solutions has been introduced to the national market, always supported by specialised technical and scientific expertise.

Learn more about the partnership between Quilaban and QIAGEN.